Celiac Disease Market Outlook 2034: Growth Trends, Competitive Landscape, and Future Opportunities

Celiac Disease Market Outlook 2034: Growth Trends, Competitive Landscape, and Future Opportunities - DelveInsight https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/report-store/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/celiac-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/consulting DelveInsight's "Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market ForecastSome of the key facts of the Celiac Disease Market Report:• The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).• In September 2026, Novartis has paused its autoimmune CAR-T clinical trials following three reported deaths. Meanwhile, this week's major developments included the first gene therapy for Huntington's disease being submitted to the FDA, an mRNA-based influenza vaccine progressing to Phase 3 trials, promising developments in an antibody therapy for celiac disease, and several other key updates.• In September 2026, Teva announced positive results from a Phase 2a clinical trial evaluating its investigational therapy, TEV-408, for celiac disease, a chronic autoimmune condition with no currently approved drug treatments. The study enrolled 50 adults and successfully met its primary endpoint, demonstrating that TEV-408 significantly and meaningfully reduced gluten-induced intestinal damage compared with placebo. The antibody also showed favorable effects in decreasing intestinal inflammation and improving gastrointestinal symptoms.• In July 2026, Argenx has entered into a definitive agreement to acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion. The acquisition strengthens argenx's immunology pipeline by adding a first-in-class anti-CD122 monoclonal antibody that has shown early clinical promise in vitiligo and celiac disease. The clinical-stage therapy targets a key signaling pathway involving T cells and natural killer (NK) cells, expanding argenx's portfolio of innovative immune-mediated disease treatments.• In February 2026, Forte Biosciences initiated enrollment in the Phase II FB102-301 trial, evaluating FB102 in adults with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. The study is designed to assess the safety and efficacy of FB102 as a potential disease-modifying therapy• In June 2025, Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune and related disorders, has reported positive results from a Phase 1b trial of its lead candidate, FB102 (study FB102-101), in celiac disease.• In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug TEV-53408, an anti-IL-15 antibody, for the treatment of celiac disease in patients adhering to a gluten-free diet. TEV-53408 is currently undergoing evaluation in a Phase 2a clinical trial to determine its safety and effectiveness in adults with celiac disease. The FDA's Fast Track program aims to speed up the development and review of therapies for serious conditions with significant unmet medical needs.• In February 2025, PhaseV, a leader in software and machine learning (ML) solutions for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials targeting various GI disorders, including inflammatory bowel disease (IBD), celiac disease, and eosinophilic gastrointestinal disease (EGID). By applying adaptive trial methodologies, the partnership seeks to boost trial efficiency and improve patient outcomes, ultimately accelerating the development of innovative therapies for individuals suffering from these complex GI conditions.• In October 2024, Topas Therapeutics reported positive topline results from its Phase IIa trial of TPM502 in celiac disease patients. The findings provide the first clinical proof of concept for the company's proprietary nanoparticle platform, highlighting its potential to induce targeted, antigen-specific tolerogenic effects.• In September 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to manage diseases, has commenced its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. This randomized, placebo-controlled study, incorporating a controlled gluten challenge, aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000.• In May 2024, Entero Therapeutics, Inc. (previously known as First Wave BioPharma, Inc.) has introduced its new corporate identity and website. This rebranding comes after its recent merger with ImmunogenX and underscores the company's commitment to tackling unmet needs in gastrointestinal health, including celiac disease, a condition that currently lacks approved treatments.• In March 2024, First Wave BioPharma completed an all-stock acquisition of ImmunogenX, forming a unified entity aimed at advancing a gastrointestinal pipeline featuring several late-stage clinical assets, including latiglutenase. Additionally, the company revealed that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) in Washington.• In 2023, the United States represented the largest portion of the celiac disease market among the 7MM, contributing roughly 70% to the overall market.• Among the EU4 and the UK, Italy had the highest market valuation for celiac disease, estimated at around USD 200 million.• At present, a gluten-free diet is the sole effective treatment for celiac disease, with the market in Japan valued at around USD 1,500 million in 2023.• Celiac disease exhibits a significant gender imbalance, primarily affecting females. In Germany, for example, around 60% of diagnosed cases are female.• In 2023, classical celiac disease accounted for approximately 30% of all celiac disease cases in Japan.• According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, or around 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans with celiac disease remain undiagnosed or are incorrectly diagnosed with other medical conditions.• According to Stahl et al. (2023), Celiac disease is a prevalent chronic condition globally, with an aggregated prevalence of 1.4%, though it can be significantly higher in specific regions. In a prospective birth cohort study involving infants at risk for celiac disease in Europe and the United States, the incidence was estimated to be 3% in Sweden and 2.4% in Colorado.• According to the Celiac Disease Foundation, celiac disease is a significant autoimmune disorder estimated to impact 1 in 100 people globally. Additionally, 2.5 million Americans remain undiagnosed and are susceptible to potential long-term health issues.• Key Celiac Disease Companies: Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others• Key Celiac Disease Therapies: TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others• The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males• The Celiac Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.Celiac Disease OverviewCeliac disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. When individuals with celiac disease consume gluten, their immune system responds by damaging the lining of the small intestine, leading to malabsorption of nutrients and a range of symptoms.Get a Free sample for the Celiac Disease Market Report:Celiac Disease EpidemiologyThe epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.Celiac Disease Epidemiology Segmentation:The Celiac Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:• Total Prevalent Population of Celiac Disease in the 7MM• Total Diagnosed Prevalent Population of Celiac Disease in the 7MM• Type-specific Prevalent Population of Celiac Disease in the 7MM• Gender-specific Prevalent Population of Celiac Disease in the 7MM• Age-specific Distribution of Celiac Disease in the 7MMDownload the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Epidemiology ForecastCeliac Disease Drugs Uptake and Pipeline Development ActivitiesThe drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.Celiac Disease Therapies and Key Companies• TAK-062: Takeda• KAN-101: AnokionSA• MTX 101: Mozart Therapeutics• AMY02: AMYRA Biotech AG• EQ102: Equillium Bio.• DONQ52: Chugai Pharmaceutical Co., Ltd.• CALY-002: Calypso Biotech• Latiglutenase : ImmunogenX, Inc.• Ordesekimab: Amgen Inc.Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment MarketCeliac Disease Market Drivers• Rising prevalence of celiac disease worldwide, supported by improved awareness and increased screening, is expanding the diagnosed patient population.• Growing adoption of serological and genetic testing is enabling earlier and more accurate diagnosis, driving treatment demand.• Increasing awareness among healthcare professionals and patients is reducing underdiagnosis and encouraging timely disease management.• Robust pipeline of novel therapeutics, including gluten-degrading enzymes, immune-modulating therapies, and tight junction regulators, is expected to transform the treatment landscape beyond a gluten-free diet.• Limitations of a strict gluten-free diet (GFD), including compliance challenges and accidental gluten exposure, are creating demand for adjunctive and alternative therapies.Celiac Disease Market Barriers• The gluten-free diet remains the standard of care, reducing the immediate need for pharmacological therapies in many patients.• High rates of undiagnosed or misdiagnosed cases continue to limit the addressable treatment population.• Complex disease pathophysiology and the lack of validated surrogate endpoints make drug development challenging.• Clinical trial recruitment difficulties, driven by strict eligibility criteria and dietary adherence requirements, can delay product development.• Potential safety concerns associated with long-term immune-modulating therapies may affect regulatory approval and physician acceptance.Scope of the Celiac Disease Market Report• Study Period: 2020-2034• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]• Key Celiac Disease Companies: Takeda, AnokionSA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc., Amgen Inc., and others• Key Celiac Disease Therapies: TAK-062, KAN-101, MTX 101, AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies• Celiac Disease Unmet Needs, KOL's views, Analyst's views, Celiac Disease Market Access and ReimbursementMedia ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: info@delveinsight.comCity: AlbanyState: New YorkCountry: United StatesWebsite:About DelveInsightDelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.